{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:22:37Z","timestamp":1769577757433,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cpt.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:51:19Z","timestamp":1737431479000},"page":"434-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic burden and health-related quality of life in Chinese patients with mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linna","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenrong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2025.01.005_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/cancers14010145","article-title":"Contemporary treatment patterns and response in relapsed\/refractory cutaneous T-cell lymphoma (CTCL) across five European countries","volume":"14","author":"Assaf","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cpt.2025.01.005_bib2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cpt.2025.01.005_bib3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/10428194.2012.729831","article-title":"Incidence and survival patterns of cutaneous T-cell lymphomas in the United States","volume":"54","author":"Imam","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cpt.2025.01.005_bib4","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.ejca.2013.04.018","article-title":"A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome","volume":"49","author":"Benton","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpt.2025.01.005_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cpt.2025.01.005_bib6","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2025.01.005_bib7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.24876","article-title":"Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Wilcox","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpt.2025.01.005_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome \u2013 update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpt.2025.01.005_bib9","first-page":"2","article-title":"Clinical practice guideline for lymphoma in China (2023 version)","volume":"30","author":"Shi","year":"2023","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"10.1016\/j.cpt.2025.01.005_bib10","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/jdv.17570","article-title":"Quality of life in patients with mycosis fungoides and Sezary syndrome: a systematic review of the literature","volume":"35","author":"Ottevanger","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.cpt.2025.01.005_bib11","first-page":"190","article-title":"Health-related quality of life and economic implications of cutaneous T-cell lymphoma","volume":"182","author":"Semenov","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cpt.2025.01.005_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjd.19298","article-title":"Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma","volume":"184","author":"Bhat","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cpt.2025.01.005_bib13","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 national cutaneous lymphoma foundation survey","volume":"107","author":"Demierre","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.cpt.2025.01.005_bib14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0889-8588(03)00111-4","article-title":"Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma","volume":"17","author":"Demierre","year":"2003","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.cpt.2025.01.005_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12185-021-03179-7","article-title":"Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia","volume":"114","author":"Lee","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cpt.2025.01.005_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12955-014-0190-4","article-title":"Development and psychometric validation of the Chinese version of Skindex-29 and Skindex-16","volume":"12","author":"He","year":"2014","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.cpt.2025.01.005_bib17","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jval.2021.03.009","article-title":"Mapping EQ-5D-3L to EQ-5D-5L","volume":"24","author":"van Hout","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.cpt.2025.01.005_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L value set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.cpt.2025.01.005_bib19","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.cpt.2025.01.005_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","article-title":"General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G)","volume":"28","author":"Brucker","year":"2005","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.cpt.2025.01.005_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2025.01.005_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2471\/BLT.05.023739","article-title":"Catastrophic household expenditure for health care in a low-income society: a study from Nouna District, Burkina Faso","volume":"84","author":"Su","year":"2006","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.cpt.2025.01.005_bib23","first-page":"2549","article-title":"Health-related quality of life measured using EQ-5D in patients with lymphomas","volume":"29","author":"Xu","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cpt.2025.01.005_bib24","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jval.2024.04.014","article-title":"EQ-5D-5L population norms for China derived from a National Health Survey","volume":"27","author":"Li","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.cpt.2025.01.005_bib25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.clinthera.2016.03.009","article-title":"Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer","volume":"38","author":"Pickard","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.cpt.2025.01.005_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12955-020-01542-6","article-title":"Factors affecting health-related quality of life in patients with skin disease: cross-sectional results from 8,789 patients with 16 skin diseases","volume":"18","author":"He","year":"2020","journal-title":"Health Qual Life Outcomes"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713225000059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713225000059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:03:05Z","timestamp":1762650185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713225000059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2949713225000059"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2025.01.005","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic burden and health-related quality of life in Chinese patients with mycosis fungoides and S\u00e9zary syndrome","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}